Vascular-directed responses of microglia produced by methamphetamine exposure: indirect evidence that microglia are involved in vascular repair? by John F. Bowyer et al.
RESEARCH Open Access
Vascular-directed responses of microglia
produced by methamphetamine exposure:
indirect evidence that microglia are
involved in vascular repair?
John F. Bowyer1,4*, Sumit Sarkar1, Karen M. Tranter1, Joseph P. Hanig2, Diane B. Miller3 and James P. O’Callaghan3
Abstract
Background: Brain microglial activations and damage responses are most commonly associated with
neurodegeneration or systemic innate immune system activation. Here, we used histological methods to focus on
microglial responses that are directed towards brain vasculature, previously undescribed, after a neurotoxic
exposure to methamphetamine.
Methods: Male rats were given doses of methamphetamine that produce pronounced hyperthermia, hypertension,
and toxicity. Identification of microglia and microglia-like cells (pericytes and possibly perivascular cells) was done
using immunoreactivity to allograft inflammatory factor 1 (Aif1 a.k.a Iba1) and alpha M integrin (Itgam a.k.a. Cd11b)
while vasculature endothelium was identified using rat endothelial cell antigen 1 (RECA-1). Regions of neuronal,
axonal, and nerve terminal degeneration were determined using Fluoro-Jade C.
Results: Dual labeling of vasculature (RECA-1) and microglia (Iba1) showed a strong association of hypertrophied
cells surrounding and juxtaposed to vasculature in the septum, medial dorsal hippocampus, piriform cortex, and
thalamus. The Iba1 labeling was more pronounced in the cell body while Cd11b more so in the processes of
activated microglia. These regions have been previously identified to have vascular leakage after neurotoxic
methamphetamine exposure. Dual labeling with Fluoro-Jade C and Iba1 indicated that there was minimal or no
evidence of neuronal damage in the septum and hippocampus where many hypertrophied Iba1-labeled cells were
found to be associated with vasculature. Although microglial activation around the prominent neurodegeneration
was found in the thalamus, there were also many examples of activated microglia associated with vasculature.
Conclusions: The data implicate microglia, and possibly related cell types, in playing a major role in responding to
methamphetamine-induced vascular damage, and possibly repair, in the absence of neurodegeneration. Identifying
brain regions with hypertrophied/activated microglial-like cells associated with vasculature has the potential for
identifying regions of more subtle examples of vascular damage and BBB compromise.
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Background
Microglia activation responses in connection with
neurotoxic insults have been investigated for now over
30 years [1–8]. Microglial responses to METH and
amphetamine (AMPH) damage to dopaminergic axons
and nerve terminals in the striatum [9, 10] and neurode-
generation in the parietal cortex, thalamus, and hippo-
campus and other limbic regions [11–13] were first
identified over 20 years ago. In most cases, it has now
been shown that microglia are not involved in producing
or exacerbating the neurodegeneration, but responding
to it [2, 3, 11–13]. This has been observed for dopamin-
ergic terminal damage in the striatum due to amphet-
amines or MPTP [14–16]. Most clearly, it was shown
that you can block the microglial response without
affecting the degree of neurodegeneration, indicating
parallel processes [14]. It has been known for some time
that microglia play a role in scavenging degenerating
neurons [17]. Although the origin and development
of microglia in the brain has been elucidated [18], the
role of microglia in disease and the neurotoxic
process is continually being reevaluated and debated
[8, 14, 19–23].
Significant microglia activation can occur just due to
systemic signals circulating in the blood such as bacterial
inflammagens, lipopolysaccharide (LPS), or damage-
associated molecular proteins [24] (DAMPs) that do not
cause neurodegeneration [14, 23]. This raises the possi-
bility that, in regions of the brain where subtle or limited
blood-brain barrier (BBB) breakdown or vascular leakage
occurs, the activation of microglia and related cells that
are adjacent to brain vasculature will occur. Histological
signs of BBB breakdown in the septum and medial
hippocampus of mouse and rat occur after a single very
high dose of METH that can be the “driving force be-
hind” the significant and prolonged signs of seizure ac-
tivity [25, 26]. As well, microglial activation via isolectin
B4 identification surrounding the vasculature is promin-
ent, particularly in the hippocampus of the mouse brain.
However, there is also a significant amount of neurode-
generation in these regions raising the possibility that
the microglial response observed may be solely due to
neurodegeneration.
Studies have indicated that other paradigms [21, 22]
used to produce METH or AMPH neurotoxicity in rat
or mouse can produce multiple focal areas (0.25 to
1 mm2) of vascular leakage within the thalamus and lim-
bic regions that appear when body temperatures are
≥41.7 °C [27, 28]. However, behavioral signs of seizure
activity are much less pronounced or absent in the
paradigm in which four injections (ranging from 5 to
10 mg/kg) are spaced over a 6-h period [26]. As well,
although neurodegeneration occurs in the thalamus, in
this paradigm, there is usually only minor axonal
damage in the more medial and ventral septum and al-
most no evidence of neurotoxicity in the hippocampus.
Therefore, in the present study, we chose this type of
dosing paradigm [29] now commonly used to produce
METH or amphetamine toxicity, which consisted of giv-
ing four injections of 5, 7.5, 10, and 10 mg/kg of METH
with 2 h in between each injection to see if there was
significant microglial activation in the septum, hippo-
campus, and thalamus and associated vasculature.
Methods
Animals
This study was carried out in accordance with the dec-
laration of Helsinki and the Guide for the Care and Use
of Laboratory Animals as adopted and promulgated by
the National Institutes of Health. The use of animal test-
ing in this study was done under protocols E7295 and
E7519 (issued to John Bowyer) that were approved by
the NCTR institutional animal care and use committee
(IACUC) which is fully accredited (Food and Drug
Administration—National Center for Toxicological Re-
search Accreditation #A4310-01) by NIH-OLAW. Sixty-
five-day-old (300–350 g) male Sprague-Dawley rats,
ninety-five total, were obtained from the Charles River
Laboratories [Crl:CD(SD)]. Upon arrival at NCTR, they
received tail tattoos for identification. Prior to testing,
rats were housed 2 per cage with food and water avail-
able ad libitum. Rats were housed on a daily 12-h light
cycle with lights on at 6:00 am and off at 6:00 pm. Dur-
ing housing, the temperature (23 °C) and humidity
(53 %) were controlled. The rats were tested between 85
and 90 days (12 weeks) of age.
Administration of METH
Dosing with METH commenced between 7:30 and 8:00
a.m. and ended between 1:30 and 2:00 p.m. Rats were in-
dividually housed during testing, and their wood chip
bedding was replaced with absorbent pads to keep the
METH animals from ingesting the wood chips. Animals
were given either four injections (each spaced by 2-h in-
tervals) of 1 ml/kg saline s.c. or four injections of METH
(5, 7.5, 10, and 10 mg/kg s.c. spaced at 2-h intervals) at
an environmental temperature of 22.5 °C. The D-METH
(D-methamphetamine HCl; Sigma-Aldrich, St. Louis,
MO) was dissolved in normal saline. The behavior and
body temperature of all animals in all groups were moni-
tored at least every hour during testing until at least 3 h
after the last/fourth injection (time of sacrifice). A flex-
ible probe was inserted approximately 7 cm into the
colon to measure body temperature. The animals given
saline at 22.5 °C remained normothermic. The lethal ef-
fects of hyperthermia in the METH group, when body
temperatures exceeded 41.6 °C, were prevented by pla-
cing the animals unrestrained on crushed ice for 15 to
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30 min in a clean, wood chip-free cage to allow their
temperatures to drop below 40.0 °C.
Animal perfusions and preparation for histological analysis
The perfusion process necessary for histological process-
ing was initiated by giving the rats a lethal dose of ap-
proximately 150 to 300 mg/kg i.p of pentobarbital and
20 to 40 mg/kg sodium phenytoin derived from a mix-
ture of Euthasol® from Vibrac AH, Inc., containing in
390 mg/ml pentobarbital and 50 mg/ml sodium pheny-
toin diluted 1:4 in sterile normal saline. When the rat’s
respiration had waned to that barely detectable, it was
perfused with 50 ml saline followed by 200 ml of 4 %
formaldehyde in 0.1 M sodium phosphate buffer (pH
7.4). Details of the perfusion process have been previ-
ously reported [11]. Brains were postfixed for 36 h in
4 % formaldehyde in 0.1 M sodium phosphate buffer
and then transferred to a 20 % sucrose and 0.1 M so-
dium phosphate buffer for at least 3 days. Sectioning of
the brain to produce 25 to 30 μm sections was per-
formed either using unfrozen fixed brain as previously
described [11] or 20- to 25-μm-thick sections using a
cryostat. For cryostat sectioning, the brain was removed
from the sucrose and rapidly frozen in crushed/pow-
dered dry ice. It was then embedded in OCT compound
(Electron Microscope Science, Hatfield, PA, USA) and
mounted on a Leica Cryostat for cutting coronal sec-
tions 20- to 25-μm thick from +1.2 to −6.0 relative to
the Bregma [30]. Approximately half of the sections were
stored at 4 °C in 0.1 M phosphate buffer pH 7.4 contain-
ing 4 % formalin until histological processing. The
remaining sections were in stored 0.1 M phosphate buf-
fer pH 7.4 containing 0.08 % sodium azide at 4 °C to
avoid loss of immunoreactivity or antigens present in
the tissue.
Immunohistological and Fluoro-Jade C labeling
Fluoro-Jade C labeling
Methods of Schmued et al. [31] with minor modifica-
tions were used to detect degenerating neurons, den-
drites, axons, and terminals in the forebrain using
Fluoro-Jade C (FJc). The modifications made results in a
slightly higher background, which increases the possibil-
ity of detecting a false positive signal, but this was
deemed necessary to enable dual labeling of FJc with
DAB immune-labeling of microglia or vasculature. Sec-
tions, either unprocessed or previously immune-labeled,
were mounted on gelatin (Sigma, 300Bloom)-coated
slides and dried at 50 °C. They were then transferred se-
quentially through solutions of 100 % ethanol (8 min),
95 % ethanol (2 min), 70 % ethanol (2 min) and two
times double-deionized water (2 min). They were then
immersed in double distilled water containing 0.06 %
potassium permanganate (4 to 6 min for immune-
labeled section or 8 to 10 min for unprocessed sections,
followed by two times double-deionized water (2 min).
Labeling was performed in a 0.0001 % FJc (Histo-Chem,
Jefferson, AR, USA) in 0.1 % acetic acid and distilled
water solution followed by rinsing in double distilled
water three times (1 min per wash) to remove excess
label. Slides were then rapidly air-dried, xylene-cleared
and cover-slipped with DPX (Fluka/Sigma, St. Louis, Mo,
USA) mounting media. In instances where sections were
double labeled with FJc and Iba-1 or Cd11b, the Iba-1 and
Cd11b labeling with DAB was performed first after which
the sections were mounted on the gelatin slides and proc-
essed with FJc. The only modification of the procedure for
double labeling was that the sections were exposed to the
permanganate solution for only 4 min.
Immunohistochemical labeling
For immune-reactive labeling of brain sections, either
single or double, the following procedures were used. In
all steps the sections, whether mounted on slides or
free-floating in incubation wells, were gently agitated on
an orbital shaker. Sections were first washed 15 min in
0.1 M phosphate buffer pH 7.4. In cases where diamino-
benzedine (DAB) was used as the chromophore, the sec-
tions were then incubated in phosphate buffer
containing 0.3 % H2O2 for 30 min to destroy the en-
dogenous peroxidases. From this point on, except with
the last step of DAB processing the incubation and
washing solutions used consisted of 0.1 M phosphate
buffer pH7.4 containing 0.4 % Triton X-100 in double
distilled water. The sections were subsequently washed
for 5 min. After a 30-min preincubation in 4 % normal
serum (from the animal that the secondary antibody was
raised in), the sections were incubated in normal serum
and the primary antibody for 1 to 2 h followed 18 to
24 h at 5 °C. The sections were then washed three times
for 10 min and incubated in secondary antibody for 1 to
2 h. In cases where only single labeling for Iba1 was
performed, the signal was amplified using the avidin and
biotinylated horseradish peroxidase macromolecular
complex (ABC, Vector Laboratories, Burlingame, CA)
and visualized with 0.4 mg/ml of 3,3′-diaminobenzidine
(DAB) in 50 mM Tris-buffer. The following primary anti-
bodies used were rabbit anti-Iba1, Wako Inc., Japan; rabbit
anti-RECA-1 from Abcam, Cambridge, USA; and mouse
anti-rat Cd11b, Abd Serotek, USA. The secondary anti-
bodies used were biotinylated goat anti-rabbit, Vector
Laboratories, Burlingame, CA, and biotinylated donkey
anti-rabbit, Jackson Immunoresearch, Philadelphia, PA).
Combined RECA-1 DAB and Iba1 TRITC fluorescent
immunohistochemistry
DAB immunolabeling of RECA-1 was performed first, as
described above, using a biotinylated goat anti-rabbit
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secondary antibody. Following DAB reaction, the sec-
tions were washed 3× (15 min/ wash) in buffer. Sections
were then pre-incubated with 10 % normal horse serum
(GIBCO, USA) for 30 min and then incubated with the
primary rabbit anti-Iba1 antibody for 2 h at room
temperature followed by 18 h at 5 °C. Sections were then
washed 3× followed by incubation in a secondary bio-
tinylated donkey anti-rabbit IgG (1:200; Jackson Immu-
noresearch, Philadelphia, PA) for 1 to 2 h. Subsequently,
they were washed three times and incubated in a
Streptavidin-TRITC (1:250, Jackson Immunoresearch,
Philadelphia, PA) for 2 h at room temperature. Sections
were then washed two times (5 min per wash) and
mounted on slides dried. Finally, the slides were cleared
in xylene and cover-slipped with DPX mounting
medium. Methods very similar to above were used for
DAB immunolabeling of Iba1 and TRITC immunolabel-
ing of GFAP to visualize microglia and astrocyte morph-
ology after METH in Fig. 9. GFAP immunolabeling was
performed using a polyclonal rabbit anti-GFAP primary
antibody (Dako/Agilent Technologies, USA).
Combined RECA-1 and Cd11b immunohistochemistry
Co-localization of integrin alpha M (complement com-
ponent 3 receptor 3 subunit) a.k.a Cd11b was also used
to identify macrophages in association with vascular
endothelia. DAB immunolabeling of CD11b was per-
formed first described in the previous section using a bi-
otinylated donkey anti-mouse secondary antibody.
Following DAB reaction, the sections were washed for
5 min in Tris-buffer followed by washing in Tris-buffer
saline (TBS). Sections were then pre-incubated with
10 % normal horse serum (GIBCO, USA) made in TBS
for 30 min and then incubated with the primary mouse
RECA-1 antibody for 24–48 h at 4 °C. After 48 h, tissue
sections were rinsed in TBS containing Triton-X for 3–
5 min for three times followed by incubation in biotinyl-
ated secondary antibody (1:200 dilution) for 2–3 h at RT
using TBS as antibody diluent. Then sections were
washed in TBS containing Triton-X for 3–5 min, and in-
cubated in Streptavidin-Alkaline Phosphatase (1:200;
Promega, USA) for 2 h are RT. Then tissue sections
were rinsed in TBS containing Triton-X for 3–5 min for
Table 1 Summary of hyperthermia, reactive microglia, and neurodegeneration after METH exposure
Brain regions
Septum Hippocampus Thalamus Parietal cortex
Rat ID Time point
(days)
















FG278 3ys 41.6 − − − − − − − 1 −
FG279 3 41.0 − − − − − − − 1 −
FG230 3 42.0 2× − − − − − − 4 −
FG288 3 41.9 3× − − − − 20 ++ 2 −
FG227 3 42.2 3× + +++ − +++ 17 + 8 +
FG268 3 42.6 3× − − − − 3 − 10 +
FG298 3 42.0 3× − + − + 5 + 10 +
FG289 3 42.7 4× − − − + 38 +++ 9 +
FG269 3 42.6 4× − + − + 27 ++ 2 −
FG228 3 42.3 5× + +++ − ++++ 132 ++++ 7 +
FG267 3 42.3 5× + ++++ − ++++ 37 +++ 4 +
FG291 3 42.2 5× + ++++ − ++++ 91 ++++ 12 +
FG311 3 42.4 5× + +++ − ++ 53 +++ 7 +
FG258 1 41.9 2× − − − − 0 − 3 −
FG259 1 42.3 3× − − − − 6 − 6 −
FG260 1 42.1 3× − − − − 0 − 3 −
FG310 1 42.2 4× +? +? +? +? 53 − 6 −
Data relating to neurodegeneration or microglia activation for the four control animals is not shown since it was all negative. The correlation between the
numbers of times body temperature was ≥41.7 °C, and the relative number of activated microglia within a region was determined using the Spearman rank-order
correlation method. The correlation coefficients were as follows: septum, r = 0.781, p = 0.0008; hippocampus, r = 0.850, p < 0.00001; thalamus, r = 0.927, p < 0.00001;
parietal cortex, r = 0.652, p < 0.014. The correlation between the numbers of times body temperature was ≥41.7 °C and the relative number of FJc within a region
was determined using the Pearson product-moment correlation. The correlation coefficients were as follows: thalamus, r = 0.714, p = 0.0061; parietal cortex,
r = 0.546, p = 0.054 not significant
aFJc positive fibers (>10 per 25-μm section per hemisphere) observed in the medial septum
bRelative number of activated Iba1 immunoreactive cells/microglia per 25-μm section per hemisphere such that per region per hemisphere: (−) indicates <5 cells
per region; (+) 5 to 20 cells; (++) 20 to 100 cells; (+++) >100 cells
cFJc positive cells per 25-μm section per hemisphere observed in thalamus or parietal cortex
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three times. Sections were incubated in substrate for al-
kaline phosphatase (nitro blue tetrazolium; ready to use)
for 1–2 min, and color reaction was monitored under
microscope. Once the reaction was complete, the tissue
sections were rinsed in TBS containing Triton-X for 3–
5 min for three times. Subsequently, sections were
mounted in distilled water containing 0.1 M PB, dried in
warmer, cleared in Xylene, cover-slipped using special
mounting medium (H-5000; Vector laboratories), and
dried overnight under the hood.
Combined Cd11b and IBA-1 immunohistochemistry
Co-localization of integrin alpha M (complement com-
ponent 3 receptor 3 subunit) a.k.a Cd11b was also used
to identify macrophages in association with another
microglial marker IBA1. DAB immunolabeling of CD11b
was performed first described in the previous section
using a biotinylated donkey anti-mouse secondary anti-
body. Following DAB reaction, the sections were washed
for 5 min in Tris-buffer followed by washing in Tris-
buffer saline (TBS). Sections were then pre-incubated
with 10 % normal horse serum (GIBCO, USA) made in
TBS for 30 min and then incubated with the primary
rabbit IBA-1 antibody for 24–48 h at 4 °C. After 48 h,
tissue sections were rinsed in TBS containing Triton-X
for 3–5 min for three times followed by incubation in bi-
otinylated secondary antibody (1:200 dilution) for 2–3 h
at RT using TBS as antibody diluent. Then sections were
washed in TBS containing Triton-X for 3–5 min, and in-
cubated in Streptavidin-Alkaline Phosphatase (1:200;
Promega) for 2 h are RT. Then tissue sections were
rinsed in TBS containing Triton-X for 3–5 min for three
times. Sections were incubated in substrate for alkaline
phosphatase (nitro blue tetrazolium; ready to use) for 1–
2 min, and color reaction was monitored under micro-
scope. Once the reaction was complete, the tissue sections
were rinsed in TBS containing Triton-X for 3–5 min for
three times. Subsequently, sections were mounted in dis-
tilled water containing 0.1 M PB, dried in warmer, cleared
in Xylene, cover-slipped using special mounting medium
Fig. 1 Microglia activation in the septum at 3 days after METH. Septal microglia were DAB immunolabeled for IBA1 and are shown at low
(left-most panels) and high magnification (right-most panels). Magnification for the three right-hand panels was the same (see magnification bar on
the top for reference). The blue arrows show where the regions of high magnification reside in the low magnification panels
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(H-5000; Vector laboratories), and dried overnight under
the hood.
Visualization
Histological examination of the slide-mounted tissue was
examined using a Nikon epifluorescent microscope 80i
(Nikon Instruments Inc., Melville, NY) and an X-Cite 120
LED light source (Excelitas Technologies®, Waltham, MA).
The following sets of filters were used for visualization
fluorescent labeling in conjunction with the histochemical
or immunohistological labeling: TRITC excitation of 533–
553 nm and an emission of 573–613 nm and FITC excita-
tion of 464.5–499.5 and an emission of 516–556 nm. Com-
binations of these filters resulted in negligible cross-talk
between the signals from individual fluorochromes, such
that there was minimal to no observable bleed-through be-
tween any of the three signals. Visualization of DAB-
labeled sections was done with incandescent illumination.
All photomicrographs of the images were taken using a
Nikon DS-Ri1 using the NIS software from Nikon.
Results
Seventeen of the 19 animals dosed with METH and
sacrificed at the 3 days time point had body temperatures
≥40.0 °C for 4 h or more and at least two episodes of
body temperatures ≥41.7 °C requiring hypothermic inter-
vention/cooling (Table 1). The remaining two animals
had body temperatures ≥40.0 °C for 4 h or more but their
peak body temperatures did not reach 41.7 °C, and thus
they did not requiring cooling. The survival rate was ap-
proximately 90 % for the METH-treated animals. As ex-
pected with this type of dosing paradigm originally
developed to in rodent to produce pronounced and pro-
longed striatal dopamine depletions and terminal damage/
destructions due to METH (or amphetamine) exposure [29,
32–35], histological evidence of dopamine terminal damage
and destruction were pronounced (data not shown).
Fig. 2 Microglia activation in the hippocampus at 3 days after METH. The microglia located in the more rostral and dorsal-medial regions of the
hippocampus were DAB immunolabeled for IBA1 and are shown at low (left-most panels) and high magnification (right-most panels). Magnification for
the three right-hand panels was the same (see magnification bar on the top for reference). The blue arrows show where the region of
high magnification resides in the low magnification panels
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Iba1 immunoreactivity, which is an often used bio-
marker for microglia [36], was used to detect microglia
in the septum, medial hippocampus, thalamus, and par-
ietal cortex. The presence of activated microglia and FJc-
positive (FJc+) cells in four brain regions are shown in
Table 1. Both activated and resting microglia can be
clearly and distinctly labeled by Iba1 immunoreactivity;
those that are activated have a greatly enlarged soma,
and often, the processes emanating from the soma are
enlarged but of lesser length. For animals sacrificed
3 days after METH exposure, the number of Iba1 immu-
noreactive activated (based on criteria stated above)
microglia in the dorsal lateral septum, anterior medial
hippocampus, and the intralaminar, ventrolateral (VL),
and ventromedial (VM) thalamus nuclei correlate posi-
tively with the number of times the body temperature of
an animal exceeded 41.7 °C (see Table 1 for details). As
well, the number of FJc+ cells in the thalamus and FJc+
fibers in the septum correlated with episodes of body
temperatures ≥41.7 °C, which was not the case for the
number of FJc+ cells present in the parietal cortex.
The morphology of the majority of the activated
microglia in the parietal cortex was of the hypertrophied
spherical soma (with concomitant loss of long fibrous
looking processes) type previously identified as being as-
sociated with degenerating neurons [2] (data not shown).
However, there were some activated microglia in this re-
gion with the morphology of the predominant type seen
in the septum and hippocampus (see below). The total
number of activated microglia in the more dorsal and lat-
eral septum (Fig. 1 and Additional file 1: Figure S1A) and
anterior medial hippocampus (Fig. 2 and Additional file 1:
Figure S2A) was in much greater numbers. In addition,
the morphology of these activated microglia with greatly
enlarged somas and significantly reduced processes, and
most were “tubular” or “worm-like” not spherical. Thus,
they did not have the appearance of activated microglia
normally associated with neurodegeneration.
Fig. 3 Pronounced microglia activation in the septum with little or no apparent neurodegeneration. Dual labeling of microglia with IBA1
immunoreactivity and FJc to detect neurodegeneration is shown in the dorsal and more lateral aspects of the septum. The three left-hand panels
show the DAB-labeled microglia with incandescent illumination while the three center, and three most right-hand panels are fluorescent images
obtained using a TRITC filter (for FJc detection of neurodegeneration). The top left and center panels from a METH-treated animal (3 days post
dosing) show that there is pronounced microglia activation with minimal evidence of neurodegeneration. The most intensely labeled
structures in these dorsal lateral regions, indicated by purple arrows, are vasculature-related. The top right-hand panel shows the FJc-labeled degenerating
puncta in the caudate putamen at high magnification of the same animal. The remaining six panels are from two different METH-treated
animals that further show there is little or no FJc evidence of neurodegeneration in many of the dorsal septal regions with activated
microglia. The purple arrows in two of the bottom panels outline a large vessel that is present. The blue arrows show where the region
of high magnification resides in the low magnification panels
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The four animals sacrificed at the 1-day time point
showed minimal or no clear classic evidence of Iba1 im-
munoreactive activated microglia in the septum or
hippocampus (Table 1 and Additional file 1: Figure S1B)
or the hippocampus or thalamus (Table 1 and Additional
file 1: Figure S2B). This, despite the fact that in two of
the animals, there was FJc evidence of significant neuro-
degeneration at the 1-day time point (Table 1), is a time
point that significantly underestimates the actual number
of neurons compared to the 3-day time point (Bowyer et
al. unpublished, [26]). Only one of the four animals
showed any early evidence microglia activation in the
septum with either Iba1 or Cd11b [36] (biomarker for
microglia) or soma enlargement (data not shown). In con-
trast, in the caudate putamen, all four of the animals
showed clear evidence that microglial activation was
underway at 1 day post METH (Additional file 1:
Figure S2B) which has been previously reported by
several laboratories [16, 37–39]. There was virtually no
evidence in any brain region, in any of the four ani-
mals, examined at either the 1 or 3 days time points,
of Iba1 or Cd11b immune-reactive macrophages
invading the CNS or intercalating/invading into the
brain vasculature.
FJc labeling in the cortex and particularly the thalamus
revealed the loss of cell bodies (neurons) and their
dendrites and axonal-like process/terminals (Table 1,
Additional file 1: Figure S3A). In the ventral and more
medial septum, there was evidence of FJc+ fibers of pas-
sage but very few (ventral medial septum) or no instances
of FJc labeling indicating cell body loss (Additional file 1:
Figure S3B). Dual labeling for Iba1 immunoreactivity and
FJc indicated that most of the activated microglia immuno-
reactive for Iba1 that were present in the dorsal and central
lateral septum were found in regions in which there was
no FJc labeling (Fig. 3). In fact, there were areas in the cen-
tral/mid-septum with significant FJc fiber labeling where
the no juxtaposed activated microglia are found.
There was little or no FJc labeling in the hippocampus
that could be associated with any type of neurodegenera-
tion in any of the animals (Additional file 1: Figure S4).
Figure 4 shows dual labeling for FJc and Iba1 immuno-
reactivity in the anterior medial hippocampus as well.
We modified the original methods of Schmued et al.
Fig. 4 Pronounced microglia activation occurs with little or no apparent neurodegeneration. Dual labeling of microglia with IBA1 immunoreactivity
and FJc to detect neurodegeneration is shown in the rostral and dorsal-medial area of the hippocampus. Pronounced microglial activation can be seen
in the three left-hand panels, each for a different METH-treated animals (IDs present at the top left of panels). There was no evidence in this region in
any of the three animals for terminal, axonal, or cell body labeling degeneration from FJc labeling in the remaining six panels. Again, as seen in the
septum, the most intensely labeled structures were some of the vasculature present. The blue arrows show where the region of high magnification
resides in the low magnification panels
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[31] such that faint FJc labeling of other structures such
as vasculature can be seen in some cases. Because of
this, the fainter images of vasculature, probably endothe-
lium, can be seen in Fig. 4. Note that in this figure,
vascular-like structures faintly labeled with FJc appear
juxtaposed to activated microglia.
Double labeling to identify both vascular endothelia
and microglia was performed to discern whether or not
the activated microglia were associated with vasculature
in the septum, hippocampus, and thalamus. This was ac-
complished using antibodies to two markers Cd11b and
Iba1 for microglia and RECA-1 antibody for endothelia.
Combinations of either TRITC-labeled Iba1 immunore-
activity and DAB-labeled RECA-1 immunoreactivity or
DAB-labeled Cd11b immunoreactivity and nitro blue
tetrazolium-labeled RECA-1 immunoreactivity to iden-
tify vascular endothelium show examples of the many
close associations of endothelium with activated micro-
glia in (Fig. 5, septum; Fig. 6, hippocampus; Fig. 7 VL/
VM thalamus) 3 days after METH. In Fig. 6, the purple
arrows show a region of very intense activation of
microglia surrounding regions where vascular damage is
intense in the hippocampus.
Double labeling with DAB-labeled Cd11b immunore-
activity for microglia and blue tetrazolium-labeled
RECA1 for vasculature again shows the close association
of many/most of the activated microglia with vasculature
in both the septum (panels A and B) and the ventrolat-
eral thalamus (panel c, Fig. 8). In panel D, the microglia
can be seen double labeled with DAB-labeled Cd11b im-
munoreactivity and blue tetrazolium-labeled Iba1 immu-
noreactivity. There is a very close overlap in labeling
between the two microglial markers. However, in the ac-
tivated microglia, the Cd11b tends to be located in the
regions of the microglia more distal to the cell body
(more filamentous processes) while the IBA1 is more
concentrated in the central regions of the microglia.
Figure 9a–c shows the morphology of astrocytes sur-
rounding the activated microglia in the dorsal lateral
septum, medial anterior hippocampus, and the VL/VM
thalamus at 3 days after METH. The swollen and elon-
gated activated DAB-IBA1-labeled microglia are clearly
seen under incandescent light (remember from Fig. 8
that the DAB-IBA1 is not labeling the many of distal
processes of these activated microglia). The astrocytes in
these three brain regions appeared to be somewhat
Fig. 5 Activated microglia in septum associated with vasculature after METH. Septal sections from a control and two METH-treated animals were
double labeled using DAB labeling of an antibody to RECA1 and TRITC labeling of an antibody to IBA1. The far left panels show the DAB-labeled
RECA1 immunoreactivity to vasculature through visible light and the middle panels show the TRITC-labeled IBA1 immunoreactivity to microglia
through fluorescent illumination. The three far right panels are a merger of the first two panels. The purple arrows show regions of
particular interest (see the “Results” section for details). All panels are of the same magnification
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“swollen” and of a slightly different morphology. How-
ever, there are no discrete areas within any of the three
regions where the morphology of the astrocytes juxta-
pose to the activated microglia is altered. More extensive
data from DAB-GFAP labeling of astrocytes in the
septum, hippocampus, and thalamus also indicate that
there is a general mild hypertrophy in these regions, but
there are no discrete areas within the regions where
there is a distinctive change in astrocyte morphology
(Additional file 1: Figure S9).
Discussion
Much has been learned within the last 10 years about
microglia including their origin and early integration
into the newly developing brain [18, 40], role in both
neurological disease [3, 19], and response to neurotoxic
insults [2]. However, most of the research relating to
microglia focuses on their interaction with neurons in-
cluding the formation of synapses [19], their role in the
repair and support of damaged neurons [3, 17], and their
proposed responses resulting in adverse neuroinflamma-
tion [41]. However, it is clear from very recent research
that much is still unknown about the role and
importance of microglia in the adult brain under normal
conditions or after neurotoxic insult [14, 22, 42–44].
The results of this investigation indicate that activated
microglia associate closely with vasculature in regions
such as the septum and hippocampus where there is
minimal or no evidence of neurodegeneration after
METH with the dosing paradigm we employed in the
present experiments.
Microglia serve as microsensors of underlying path-
ology and are activated at sites of neural damage [45].
Previous research looking at microglial responses to
METH and amphetamine toxicity have focused on re-
gions of neurodegeneration, both axonal/terminal de-
generation or neuronal (cell body) death [9–11, 13, 25,
39, 46]. In such research, we have noted that microglia
have appeared to surround vasculature in regions of
neurodegeneration in the hippocampus after METH
[25]. However, in those studies, the METH exposure was
severe enough to produce status epilepticus and signifi-
cant neurodegeneration of pyramidal neurons (particu-
larly in the CA2 and CA3 regions) as well as evidence of
protracted BBB breakdown in the hippocampus. This left
open the possibility that either microglia were merely
Fig. 6 Activated microglia in hippocampus associated with vasculature after METH. Hippocampal sections from a control and two METH-treated
animals were double labeled using DAB labeling of an antibody to RECA1 and TRITC labeling of an antibody to IBA1. The far left panels show the
DAB-labeled RECA1 immunoreactivity to vasculature through visible light and the middle panels show the TRITC-labeled IBA1 immunoreactivity to
microglia through fluorescent illumination. The far right panels are a merger of the first two panels. The indigo arrows show regions of particular
interest (see the “Results” section for details). All panels are of the same magnification
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responding to intense neurodegeneration or that macro-
phages had entered the brain in the regions of such se-
vere damage and altered their morphology to resemble
microglia. We have also seen similar effects in the thal-
amus with neurotoxic exposures to amphetamine where
microglia appear to surround vasculature in the thal-
amus (unpublished data, [26]). Although there was little
evidence of BBB disruption at this time point after am-
phetamine in this region, the microglia were observed in
regions of significant neurodegeneration.
There is a significant literature related to amphetamine
and METH with respect to adverse effects on brain vas-
culature and how this may be related to hyperthermia
and neurotoxicity. Initially, it was observed that even a
single dose of METH can produce small discrete regions
of vascular leakage in several brain regions of laboratory
animals when body temperatures exceed ≈41.6 °C [28,
47]. Some of these regions coincided with where am-
phetamines have been shown to produce neurotoxicity.
A later study, using the same dosing paradigm as used
in our present study (but substituting amphetamine for
METH), observed the same discrete vascular leakage
(≤1.0 mm in diameter) to occur throughout the entire
drug exposure (multiple injections over time) [27]. This
leakage lasted only briefly (less than 2 h) during the
amphetamine administration. However, a single adminis-
tration/injection of a very high dose of METH or am-
phetamine (40 mg/kg) can produce even longer lasting
(6 to 12 h) and more extensive BBB leakage (in the
septum, anterior medial hippocampus, and amygdala nu-
clei) that results in significant neurodegeneration in
these regions [25, 26].
Much less is known with respect to how the vascular
damage that is produced by amphetamines relates to the
hypertension and reduced blood flow that may occur
during exposure. A single dose of METH has been
shown to produce prolonged reduced perfusion [48],
which could certainly adversely affect neuronal function
and lead to neurotoxicity. As well, neurotoxic exposure
to amphetamine produces changes lasting for at least
1 day in the cortex, meninges, and associated vascula-
ture indicating adverse vascular events have occurred in
the cortical surface vasculature [49, 50]. Others have re-
ported neurotoxicity and microglia activation in the
caudate putamen after amphetamines that may be re-
lated to dopamine receptor interactions [51, 52], effects
subsequent to vascular alterations, or damage [53]. Thus,
in light of the preceding discussion, it is not entirely
Fig. 7 Activated microglia in the thalamus associated with vasculature after METH. Thalamic sections from a control and two METH-treated
animals were double labeled using DAB labeling of an antibody to RECA1 and TRITC labeling of an antibody to IBA1. The far left panels show the
DAB-labeled RECA1 immunoreactivity to vasculature through visible light and the middle panels show the TRITC-labeled IBA1 immunoreactivity to
microglia through fluorescent illumination. The far right panels are a merger of the first two panels. The indigo arrows show regions of particular
interest (see the “Results” section for details). All panels are of the same magnification
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unexpected that microglia might respond to just vascular
damage as well as neuronal damage.
Other studies have noted that microglia can be acti-
vated in the absence of underlying neurodegeneration,
but these effects are still classified as neuroimmune re-
sponses (e.g., [14, 24]). Similar to those studies, evidence
of neurodegeneration in the septum and hippocampus
were not observed in the present study yet activated
microglia surrounding vasculature in regions of the
septum and hippocampus were seen after METH. Such
activation was not seen in other regions of the forebrain
except in two animals that had such activated microglia
in the piriform cortex and amygdala (data not shown).
The morphology of the activated microglia in septum
and hippocampus was not that of enlarged spheres with
radial processes that can be seen surrounding degenerat-
ing neurons but of a swollen, elongated tubular form
with seemingly shrunken processes as stained with
IBA1. However, double labeling immune-labeling with
Cd11b indicated that the processes of these activated
microglia may not have shrunk in size but that IBA1
levels in the processes were greatly reduced or not
present and that Cd11b was present distally. As well,
there is no evidence of BBB breakdown as determined
by IgG immunereactivity or macrophage invasion in the
brain either 1 day or 3 days post METH. Even in the
ventrolateral thalamic nuclei and ventromedial thal-
amic nucleus, where significant neurodegeneration oc-
curred, there were at least an equal number of the
activated tubular-shaped microglia closely associated
with vasculature.
Pericytes also play an important role in capillary flow,
angiogenesis, blood-brain barrier, and immune re-
sponses, and they are very similar to microglia in tran-
scriptome expression profile [51, 52]. Although some of
the IBA1 expressing cells surrounding the vasculature
seen in our studies may have been or be pericytes, the
vast number observed in the hippocampus, septum, and
thalamus would seem to be far too great to be just peri-
cytes. Moreover, there morphology of most of these
IBA1-positive cells does not seem to fit that reported for
pericytes [53]. However, since there are no clear/certain
histological markers that distinguish pericytes from
microglia, we cannot definitively determine the percent-
age of pericytes that might also be IBA1 positive and as-
sociated with vasculature in these regions.
It is not clear how the astrocytes are interacting with
the microglia in the septum, hippocampus, or thalamus
Fig. 8 Activated microglia immunoreactive for Cd11b are shown in association with vasculature after METH. DAB immunolabeling of Cd11 to
detect microglia and alkaline phosphatase/tetrazolium-immunolabeling of RECA1 were performed in sections of a METH animal. Shown are the
associations of activated microglia with vasculature in the septum in panels a and b or the thalamus in panel c in visible light. Double labeling of
microglia with DAB immunolabeling for Cd11b and alkaline phosphatase/tetrazolium-immunolabeling for IBA1 is shown in panel d. Magnification
bars in lower left-hand corner
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that are activated 3 days after METH exposure. There
appears to be a perceptible modest hypertrophy of the
astrocytes in these three regions, but it is region-wide
and not in conjunction with the specific areas of micro-
glial activation surrounding the vasculature. Areas with
modest toxicant-induced neural damage can result in
increases in levels of the astrocytic protein, GFAP, in the
absence of an apparent astrocytic hypertrophy [38], an
effect often preceded by microglia activation in the same
region [38]. Thus, it is possible that a small degree of
METH-induced damage, undetectable via FJc, in these
areas, is responsible for the observed modest astrocyte
Fig. 9 Astrocyte morphology in regions of METH-induced microglial activation. Dual labeling with DAB in conjunction with IBA1 immunoreactivity
and TRITC for GFAP immunolabeling shows the morphology of astrocytes in the septum (top 6 panels), hippocampus (middle 6 panels), and
thalamus (bottom 6 panels) in regions in conjunction with activated microglia after METH. The left-hand column of panels shows the IBA1-labeled
microglia under incandescent illumination while the center column of panels shows the fluorescent images of the TRITC-labeled astrocytes. The
right-hand column of panels is a merger of the incandescent and fluorescent images. All panels are of the same magnification (see the
upper left-hand panel for magnification reference)
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responses. However, they do not explain the close
responses/associations of microglia with specific vascula-
ture and not neurons.
Conclusions
The simplest and, in our opinion, the most logical ex-
planation for the presence of activated microglia sur-
rounding the vasculature in two discrete regions of the
brain where there is no neurodegeneration would be that
the microglia are responding to METH-induced vascular
damage. This was facilitated by multiple episodes of
hyperthermia (an exposure comparable to heat stroke)
and hypertension that was produced by the METH ex-
posure. It thus follows that when more episodes of
hyperthermia occur, the vascular damage and microglial
activation in the septum and hippocampus are more
likely to occur and more intense. The METH exposure
we employed only produces transient vascular disrup-
tions lasting less than 1 to 2 h and is most commonly
seen in the thalamus, septum, piriform cortex, and med-
ial ventral hippocampus [26–28]. This may be sufficient
enough to allow cytokines normally excluded from the
brain or the damage-associated proteins (DAMPs) pro-
duced by METH exposure [54] to enter the brain and
activate the microglia. On the other hand, it may be that
adversely affected brain vascular endothelia are directly
signaling the microglia through some unknown messen-
ger(s) signaling pathway. If this is the case, then the term
cerebrovascular-induced brain inflammation would be a
more appropriate characterization rather than describing
it as neuroinflammation. It follows that detection of such
activated microglia several days after an “adverse” event
occurring in brain could be used as a biomarker indicat-
ing that some vascular damage or “irritation” had
occurred.
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